Findings support once‑daily dosing and reinforce PALI‑2108’s potential More: Palisade Bio reports phase 1a/b data showing colon‑targeted exposure Source: News
read more
Study expands evaluation of survivin‑targeting vaccine More: MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours Source: News
read moreWith a better-than-expected first quarter in the books, Pfizer—continuing to grapple with the post-pandemic overhang from its COVID-19 franchise—is sticking with the sales forecast it set earlier this year, raising questions from at least one analyst about whether it could
read moreNovartis is continuing its multiyear overhaul with new plans to shutter its production facility in Wehr, Germany, by 2028. The move, announced Tuesday, will eliminate about 220 jobs, according to Novartis. More: Novartis to close German manufacturing site, cutting 220
read moreThe German vaccine maker plans to wind down operations at a handful of its sites in Germany plus one in Singapore, putting as many as 1,860 jobs on the chopping block. More: BioNTech to slash 1,860 jobs, exit sites in
read moreFresh off gaining an FDA expansion for Auvelity as a treatment for agitation associated with Alzheimer’s disease, Axsome Therapeutics has projected peak sales for the non-antipsychotic drug to reach $8 billion. More: After Alzheimer's agitation nod, Axsome jacks up Auvelity's
read more© 1994 - 2026 B.M. Pharmaceuticals